|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arzumanyan A, Reis HM and Feitelson MA:
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular
carcinoma. Nat Rev Cancer. 13:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Squires RH, Ng V, Romero R, Ekong U,
Hardikar W, Emre S and Mazariegos GV: Evaluation of the pediatric
patient for liver transplantation: 2014 practice guideline by the
American Association for the Study of Liver Diseases, American
Society of Transplantation and the North American Society for
Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr
Gastroenterol Nutr. 59:112–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lo CM: Liver transplantation in 2012:
Transplantation for liver cancer - more with better results. Nat
Rev Gastroenterol Hepatol. 10:74–76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lie PP, Cheng CY and Mruk DD: Signalling
pathways regulating the blood-testis barrier. Int J Biochem Cell
Biol. 45:621–625. 2013. View Article : Google Scholar :
|
|
6
|
Kandori H, Sudo Y and Furutani Y:
Protein-protein interaction changes in an archaeal light-signal
transduction. J Biomed Biotechnol. 2010(424760)2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chakraborty C, Doss CGP, Chen L and Zhu H:
Evaluating protein-protein interaction (PPI) networks for diseases
pathway, target discovery, and drug-design using 'in silico
pharmacology'. Curr Protein Pept Sci. 15:561–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pal I and Mandal M: PI3K and Akt as
molecular targets for cancer therapy: Current clinical outcomes.
Acta Pharmacol Sin. 33:1441–1458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Danielsen SA, Eide PW, Nesbakken A, Guren
T, Leithe E and Lothe RA: Portrait of the PI3K/AKT pathway in
colorectal cancer. Biochim Biophys Acta. 1855:104–121. 2015.
|
|
10
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sabine VS, Crozier C, Brookes CL, Drake C,
Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Markopoulos C,
Dirix L, et al: Mutational analysis of PI3K/AKT signaling pathway
in tamoxifen exemestane adjuvant multinational pathology study. J
Clin Oncol. 32:2951–2958. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Safdari Y, Khalili M, Ebrahimzadeh MA,
Yazdani Y and Farajnia S: Natural inhibitors of PI3K/AKT signaling
in breast cancer: Emphasis on newly-discovered molecular mechanisms
of action. Pharmacol Res. 93:1–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matsuoka T and Yashiro M: The role of
PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel).
6:1441–1463. 2014. View Article : Google Scholar
|
|
14
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jacinto E, Facchinetti V, Liu D, Soto N,
Wei S, Jung SY, Huang Q, Qin J and Su B: SIN1/MIP1 maintains
rictor-mTOR complex integrity and regulates Akt phosphorylation and
substrate specificity. Cell. 127:125–137. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR,
Pfeffer LM and Donner DB: NF-kappaB activation by tumour necrosis
factor requires the Akt serine-threonine kinase. Nature. 401:82–85.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu Y and Wahl LM: Production of matrix
metalloproteinase-9 by activated human monocytes involves a
phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. J
Leukoc Biol. 78:259–265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vandermoere F, El Yazidi-Belkoura I,
Adriaenssens E, Lemoine J and Hondermarck H: The antiapoptotic
effect of fibroblast growth factor-2 is mediated through nuclear
factor-kappaB activation induced via interaction between Akt and
IkappaB kinase-beta in breast cancer cells. Oncogene. 24:5482–5491.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tu CC, Cheng LH, Hsu HH, Chen LM, Lin YM,
Chen MC, Lee NH, Tsai FJ, Huang CY and Wu WJ: Activation of snail
and EMT-like signaling via the IKKαβ/NF-κB pathway in
Apicidin-resistant HA22T hepatocellular carcinoma cells. Chin J
Physiol. 56:326–333. 2013. View Article : Google Scholar
|
|
21
|
Noh JH, Bae HJ, Eun JW, Shen Q, Park SJ,
Kim HS, Nam B, Shin WC, Lee EK, Lee K, et al: HDAC2 provides a
critical support to malignant progression of hepatocellular
carcinoma through feedback control of mTORC1 and AKT. Cancer Res.
74:1728–1738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang R, Cao X, Wang C, Hou L, Nie J, Zhou
M and Feng Y: An antitumor peptide from Musca domestica pupae
(MATP) induces apoptosis in HepG2 cells through a JNK-mediated and
Akt-mediated NF-κB pathway. Anticancer Drugs. 23:827–835. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yuan Z, Kim D, Shu S, Wu J, Guo J, Xiao L,
Kaneko S, Coppola D and Cheng JQ: Phosphoinositide 3-kinase/Akt
inhibits MST1-mediated pro-apoptotic signaling through
phosphorylation of threonine 120. J Biol Chem. 285:3815–3824. 2010.
View Article : Google Scholar
|
|
24
|
Wang CY, Tsai AC, Peng CY, Chang YL, Lee
KH, Teng CM and Pan SL: Dehydrocostuslactone suppresses
angiogenesis in vitro and in vivo through inhibition of Akt/GSK-3β
and mTOR signaling pathways. PLoS One. 7:e311952012. View Article : Google Scholar
|
|
25
|
Su Y, Fu C, Ishikawa S, Stella A, Kojima
M, Shitoh K, Schreiber EM, Day BW and Liu B: APC is essential for
targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin
ligase. Mol Cell. 32:652–661. 2008. View Article : Google Scholar
|
|
26
|
Bauer L, Langer R, Becker K, Hapfelmeier
A, Ott K, Novotny A, Höfler H and Keller G: Expression profiling of
stem cell-related genes in neoadjuvant-treated gastric cancer: A
NOTCH2, GSK3B and β-catenin gene signature predicts survival. PLoS
One. 7:e445662012. View Article : Google Scholar
|
|
27
|
Hsieh CH, Cheng LH, Hsu HH, Ho TJ, Tu CC,
Lin YM, Chen MC, Tsai FJ, Hsieh YL and Huang CY: Apicidin-resistant
HA22T hepatocellular carcinoma cells strongly activated the
Wnt/β-catenin signaling pathway and MMP-2 expression via the
IGF-IR/PI3K/Akt signaling pathway enhancing cell metastatic effect.
Biosci Biotechnol Biochem. 77:2397–2404. 2013. View Article : Google Scholar
|
|
28
|
Mavila N, James D, Utley S, Cu N, Coblens
O, Mak K, Rountree CB, Kahn M and Wang KS: Fibroblast growth factor
receptor-mediated activation of AKT-β-catenin-CBP pathway regulates
survival and proliferation of murine hepatoblasts and hepatic tumor
initiating stem cells. PLoS One. 7:e504012012. View Article : Google Scholar
|
|
29
|
Liu L, Dai Y, Chen J, Zeng T, Li Y, Chen
L, Zhu YH, Li J, Li Y, Ma S, et al: Maelstrom promotes
hepatocellular carcinoma metastasis by inducing
epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail
signaling. Hepatology. 59:531–543. 2014. View Article : Google Scholar
|
|
30
|
Gotoh J, Obata M, Yoshie M, Kasai S and
Ogawa K: Cyclin D1 over-expression correlates with beta-catenin
activation, but not with H-ras mutations, and phosphorylation of
Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis.
Carcinogenesis. 24:435–442. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Woo JK, Choi Y, Oh SH, Jeong JH, Choi DH,
Seo HS and Kim CW: Mucin 1 enhances the tumor angiogenic response
by activation of the AKT signaling pathway. Oncogene. 31:2187–2198.
2012. View Article : Google Scholar
|
|
32
|
Niault TS and Baccarini M: Targets of Raf
in tumorigenesis. Carcinogenesis. 31:1165–1174. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nikolaev SI, Rimoldi D, Iseli C, Valsesia
A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete V, et
al: Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2
mutations in melanoma. Nat Genet. 44:133–139. 2012. View Article : Google Scholar
|
|
34
|
Barthwal MK, Sathyanarayana P, Kundu CN,
Rana B, Pradeep A, Sharma C, Woodgett JR and Rana A: Negative
regulation of mixed lineage kinase 3 by protein kinase B/AKT leads
to cell survival. J Biol Chem. 278:3897–3902. 2003. View Article : Google Scholar
|
|
35
|
Kim AH, Khursigara G, Sun X, Franke TF and
Chao MV: Akt phosphorylates and negatively regulates apoptosis
signal-regulating kinase 1. Mol Cell Biol. 21:893–901. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zimmermann S and Moelling K:
Phosphorylation and regulation of Raf by Akt (protein kinase B).
Science. 286:1741–1744. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kane LP, Mollenauer MN, Xu Z, Turck CW and
Weiss A: Akt-dependent phosphorylation specifically regulates Cot
induction of NF-kappa B-dependent transcription. Mol Cell Biol.
22:5962–5974. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Park HS, Kim MS, Huh SH, Park J, Chung J,
Kang SS and Choi EJ: Akt (protein kinase B) negatively regulates
SEK1 by means of protein phosphorylation. J Biol Chem.
277:2573–2578. 2002. View Article : Google Scholar
|
|
39
|
Rane MJ, Coxon PY, Powell DW, Webster R,
Klein JB, Pierce W, Ping P and McLeish KR: p38 Kinase-dependent
MAPKAPK-2 activation functions as 3-phosphoinositide-dependent
kinase-2 for Akt in human neutrophils. J Biol Chem. 276:3517–3523.
2001. View Article : Google Scholar
|
|
40
|
Nishitani Y and Matsumoto H: Ethanol
rapidly causes activation of JNK associated with ER stress under
inhibition of ADH. FEBS Lett. 580:9–14. 2006. View Article : Google Scholar
|
|
41
|
Kim JW, Lee JE, Kim MJ, Cho EG, Cho SG and
Choi EJ: Glycogen synthase kinase 3 beta is a natural activator of
mitogen-activated protein kinase/extracellular signal-regulated
kinase kinase kinase 1 (MEKK1). J Biol Chem. 278:13995–14001. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and
Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2
phosphorylation. Nat Cell Biol. 3:973–982. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ashcroft M, Ludwig RL, Woods DB, Copeland
TD, Weber HO, MacRae EJ and Vousden KH: Phosphorylation of HDM2 by
Akt. Oncogene. 21:1955–1962. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fu Z, Ren L, Wei H, Lv J, Che X, Zhu Z,
Jia J, Wang L, Lin G, Lu R, et al: Effects of Tyroserleutide on
phosphatidylinositol 3′-kinase/AKT pathway in human hepatocellular
carcinoma cell. J Drug Target. 22:146–155. 2014. View Article : Google Scholar
|
|
45
|
Wang C, Qi R, Li N, Wang Z, An H, Zhang Q,
Yu Y and Cao X: Notch1 signaling sensitizes tumor necrosis
factor-related apoptosis-inducing ligand-induced apoptosis in human
hepato-cellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53
degradation and up-regulating p53-dependent DR5 expression. J Biol
Chem. 284:16183–16190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Song J, Park S, Kim M and Shin I:
Down-regulation of Notch-dependent transcription by Akt in vitro.
FEBS Lett. 582:1693–1699. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu L, Zhu Y, Xu J, Wu K, Li J, Xu W, Liu
H, Wang S, Yin H, Chen L, et al: Notch1 activation promotes renal
cell carcinoma growth via PI3K/Akt signaling. Cancer Sci.
103:1253–1258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huntzicker EG, Hötzel K, Choy L, Che L,
Ross J, Pau G, Sharma N, Siebel CW, Chen X and French DM:
Differential effects of targeting Notch receptors in a mouse model
of liver cancer. Hepatology. 61:942–952. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Brana I, Berger R, Golan T, Haluska P,
Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani
P, et al: A parallel-arm phase I trial of the humanised anti-IGF-1R
antibody dalotuzumab in combination with the AKT inhibitor MK-2206,
the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752,
in patients with advanced solid tumours. Br J Cancer.
111:1932–1944. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fielhaber JA, Han YS, Tan J, Xing S, Biggs
CM, Joung KB and Kristof AS: Inactivation of mammalian target of
rapamycin increases STAT1 nuclear content and transcriptional
activity in alpha4- and protein phosphatase 2A-dependent fashion. J
Biol Chem. 284:24341–24353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang F, Zhang W, Li D and Zhan Q: Gadd45a
suppresses tumor angiogenesis via inhibition of the mTOR/STAT3
protein pathway. J Biol Chem. 288:6552–6560. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sekulić A, Hudson CC, Homme JL, Yin P,
Otterness DM, Karnitz LM and Abraham RT: A direct linkage between
the phosphoinositide 3-kinase-AKT signaling pathway and the
mammalian target of rapamycin in mitogen-stimulated and transformed
cells. Cancer Res. 60:3504–3513. 2000.
|
|
53
|
Dunlop EA and Tee AR: Mammalian target of
rapamycin complex 1: Signalling inputs, substrates and feedback
mechanisms. Cell Signal. 21:827–835. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mamane Y, Petroulakis E, LeBacquer O and
Sonenberg N: mTOR, translation initiation and cancer. Oncogene.
25:6416–6422. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhou Q, Lui VW and Yeo W: Targeting the
PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol.
7:1149–1167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhou L, Huang Y, Li J and Wang Z: The mTOR
pathway is associated with the poor prognosis of human
hepatocellular carcinoma. Med Oncol. 27:255–261. 2010. View Article : Google Scholar
|
|
57
|
Nissen NN1, Menon V, Bresee C, Tran TT,
Annamalai A, Poordad F, Fair JH, Klein AS, Boland B and Colquhoun
SD: Recurrent hepatocellular carcinoma after liver transplant:
identifying the high-risk patient. HPB. 13:626–632. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Nakae J, Kitamura T, Kitamura Y, Biggs WH
III, Arden KC and Accili D: The forkhead transcription factor Foxo1
regulates adipocyte differentiation. Dev Cell. 4:119–129. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hay N: Interplay between FOXO, TOR, and
Akt. Biochim Biophys Acta. 1813:1965–1970. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Nakae J, Kitamura T, Silver DL and Accili
D: The forkhead transcription factor Foxo1 (Fkhr) confers insulin
sensitivity onto glucose-6-phosphatase expression. J Clin Invest.
108:1359–1367. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Khor TO, Gul YA, Ithnin H and Seow HF:
Positive correlation between overexpression of phospho-BAD with
phosphorylated Akt at serine 473 but not threonine 308 in
colorectal carcinoma. Cancer Lett. 210:139–150. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Huang CS, Lee YR, Chen CS, Tu SH, Wang YJ,
Lee CH, Chen LC, Chang HW, Chang CH, Chih-Ming S, et al: Long-term
ethanol exposure causes human liver cancer cells to become
resistant to mitomycin C treatment through the inactivation of
bad-mediated apoptosis. Mol Carcinog. 49:728–738. 2010.PubMed/NCBI
|
|
63
|
Carrano AC and Pagano M: Role of the F-box
protein Skp2 in adhesion-dependent cell cycle progression. J Cell
Biol. 153:1381–1390. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lin HK, Wang G, Chen Z, Teruya-Feldstein
J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer
S, et al: Phosphorylation-dependent regulation of cytosolic
localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell
Biol. 11:420–432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ho C, Wang C, Mattu S, Destefanis G, Ladu
S, Delogu S, Armbruster J, Fan L, Lee SA, Jiang L, et al: AKT
(v-akt murine thymoma viral oncogene homolog 1) and N-Ras
(neuroblastoma ras viral oncogene homolog) coactivation in the
mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian
target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and
c-Myc pathways. Hepatology. 55:833–845. 2012. View Article : Google Scholar :
|
|
66
|
Lu NZ, Wardell SE, Burnstein KL, Defranco
D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel
NL, et al: International Union of Pharmacology. LXV. The
pharmacology and classification of the nuclear receptor
superfamily: Glucocorticoid, mineralocorticoid, progesterone, and
androgen receptors. Pharmacol Rev. 58:782–797. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lin HK, Yeh S, Kang HY and Chang C: Akt
suppresses androgen-induced apoptosis by phosphorylating and
inhibiting androgen receptor. Proc Natl Acad Sci USA. 98:7200–7205.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ma WL, Jeng LB, Lai HC, Liao PY and Chang
C: Androgen receptor enhances cell adhesion and decreases cell
migration via modulating β1-integrin-AKT signaling in
hepatocellular carcinoma cells. Cancer Lett. 351:64–71. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Nie H, Cao Q, Zhu L, Gong Y, Gu J and He
Z: Acetylcholine acts on androgen receptor to promote the migration
and invasion but inhibit the apoptosis of human hepatocarcinoma.
PLoS One. 8:e616782013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hong X, Song R, Song H, Zheng T, Wang J,
Liang Y, Qi S, Lu Z, Song X, Jiang H, et al: PTEN antagonises
Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to
hepatocarcinogenesis. Gut. 63:1635–1647. 2014. View Article : Google Scholar
|
|
71
|
Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu
P, Chen KK, Lopez JP, Poon RT and Fan ST: Octamer 4 (Oct4) mediates
chemotherapeutic drug resistance in liver cancer cells through a
potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology.
52:528–539. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Vasan N, Yelensky R, Wang K, Moulder S,
Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, et
al: A targeted next-generation sequencing assay detects a high
frequency of therapeutically targetable alterations in primary and
metastatic breast cancers: Implications for clinical practice.
Oncologist. 19:453–458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kittaka N, Takemasa I, Takeda Y, Marubashi
S, Nagano H, Umeshita K, Dono K, Matsubara K, Matsuura N and Monden
M: Molecular mapping of human hepatocellular carcinoma provides
deeper biological insight from genomic data. Eur J Cancer.
44:885–897. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chan J, Ko FC, Yeung YS, Ng IO and Yam JW:
Integrin-linked kinase overexpression and its oncogenic role in
promoting tumorigenicity of hepatocellular carcinoma. PLoS One.
6:e169842011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Peroukides S, Bravou V, Varakis J,
Alexopoulos A, Kalofonos H and Papadaki H: ILK overexpression in
human hepatocellular carcinoma and liver cirrhosis correlates with
activation of Akt. Oncol Rep. 20:1337–1344. 2008.PubMed/NCBI
|
|
76
|
Cui Y, Wu W, Zhou Y, Xie Q, Liu T, Jin J
and Liu K: HSP27 expression levels are associated with the
sensitivity of hepatocellular carcinoma cells to
17-allylamino-17-demethoxygeldanamycin. Future Oncol. 9:411–418.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Nam SY, Seo HH, Park HS, An S, Kim JY,
Yang KH, Kim CS, Jeong M and Jin YW: Phosphorylation of CLK2 at
serine 34 and threonine 127 by AKT controls cell survival after
ionizing radiation. J Biol Chem. 285:31157–31163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Villagrasa P, Díaz VM, Viñas-Castells R,
Peiró S, Del Valle-Pérez B, Dave N, Rodríguez-Asiain A, Casal JI,
Lizcano JM, Duñach M, et al: Akt2 interacts with Snail1 in the
E-cadherin promoter. Oncogene. 31:4022–4033. 2012. View Article : Google Scholar
|
|
79
|
Thirumurthi U, Shen J, Xia W, LaBaff AM,
Wei Y, Li CW, Chang WC, Chen CH, Lin HK, Yu D, et al: MDM2-mediated
degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis
and trastuzumab resistance in breast cancer. Sci Signal.
7:ra712014. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zhao R, Yang HY, Shin J, Phan L, Fang L,
Che TF, Su CH, Yeung SC and Lee MH: CDK inhibitor
p57Kip2 is downregulated by Akt during HER2-mediated
tumorigenicity. Cell Cycle. 12:935–943. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zeng L, Bai M, Mittal AK, El-Jouni W, Zhou
J, Cohen DM, Zhou MI and Cohen HT: Candidate tumor suppressor and
pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.
Cancer Res. 73:5371–5380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Yang WL, Jin G, Li CF, Jeong YS, Moten A,
Xu D, Feng Z, Chen W, Cai Z, Darnay B, et al: Cycles of
ubiquitination and deubiquitination critically regulate growth
factor-mediated activation of Akt signaling. Sci Signal. 6:ra32013.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Thoreen CC, Kang SA, Chang JW, Liu Q,
Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM and Gray NS: An
ATP-competitive mammalian target of rapamycin inhibitor reveals
rapamycin-resistant functions of mTORC1. J Biol Chem.
284:8023–8032. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Yu K, Toral-Barza L, Shi C, Zhang WG,
Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, et al:
Biochemical, cellular, and in vivo activity of novel
ATP-competitive and selective inhibitors of the mammalian target of
rapamycin. Cancer Res. 69:6232–6240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
García-Martínez JM, Moran J, Clarke RG,
Gray A, Cosulich SC, Chresta CM and Alessi DR: Ku-0063794 is a
specific inhibitor of the mammalian target of rapamycin (mTOR).
Biochem J. 421:29–42. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Monaco AP: The role of mTOR inhibitors in
the management of posttransplant malignancy. Transplantation.
87:157–163. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Menon KV, Hakeem AR and Heaton ND:
Meta-analysis: Recurrence and survival following the use of
sirolimus in liver transplantation for hepatocellular carcinoma.
Aliment Pharmacol Ther. 37:411–419. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Ashworth RE and Wu J: Mammalian target of
rapamycin inhibition in hepatocellular carcinoma. World J Hepatol.
6:776–782. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhu AX, Abrams TA, Miksad R, Blaszkowsky
LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag
D, et al: Phase 1/2 study of everolimus in advanced hepatocellular
carcinoma. Cancer. 117:5094–5102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chen L, Shiah HS, Chen CY, Lin YJ, Lin PW,
Su WC and Chang JY: Randomized, phase I, and pharmacokinetic (PK)
study of RAD001, and mTOR inhibitor, in patients (pts) with
advanced hepatocellular carcinoma (HCC). J Clin Oncol.
27(4587)2009.
|
|
91
|
Zhao B, Ma Y, Xu Z, Wang J, Wang F, Wang
D, Pan S, Wu Y, Pan H, Xu D, et al: Hydroxytyrosol, a natural
molecule from olive oil, suppresses the growth of human
hepatocellular carcinoma cells via inactivating AKT and nuclear
factor-kappa B pathways. Cancer Lett. 347:79–87. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Omar HA: Arafa el SA, Maghrabi IA and Weng
JR: Sensitization of hepatocellular carcinoma cells to Apo2L/TRAIL
by a novel Akt/NF-kappaB signalling inhibitor. Basic Clin Pharmacol
Toxicol. 114:464–471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Lee SJ, Hwang JW, Yim H, Yim HJ, Woo SU,
Suh SJ, Hyun JJ, Jung SW, Koo JS, Kim JH, et al: Synergistic effect
of simvastatin plus NS398 on inhibition of proliferation and
survival in hepatocellular carcinoma cell line. J Gastroenterol
Hepatol. 29:1299–1307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Zheng YH, Yin LH, Grahn TH, Ye AF, Zhao YR
and Zhang QY: Anticancer effects of baicalein on hepatocellular
carcinoma cells. Phytother Res. 28:1342–1348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Chow AK, Ng L, Sing Li H, Cheng CW, Lam
CS, Yau TC, Cheng PN, Fan ST, Poon RT and Pang RW: Anti-tumor
efficacy of a recombinant human arginase in human hepatocellular
carcinoma. Curr Cancer Drug Targets. 12:1233–1243. 2012.PubMed/NCBI
|
|
96
|
Yang F, Deng R, Qian XJ, Chang SH, Wu XQ,
Qin J, Feng GK, Ding K and Zhu XF: Feedback loops blockade
potentiates apoptosis induction and antitumor activity of a novel
AKT inhibitor DC120 in human liver cancer. Cell Death Dis.
5:e11142014. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Vassilev LT, Vu BT, Graves B, Carvajal D,
Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et
al: In vivo activation of the p53 pathway by small-molecule
antagonists of MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Li M, Zhang Z, Hill DL, Wang H and Zhang
R: Curcumin, a dietary component, has anticancer,
chemosensitization, and radiosensitization effects by
down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2
pathway. Cancer Res. 67:1988–1996. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Li M, Li Q, Zhang YH, Tian ZY, Ma HX, Zhao
J, Xie SQ and Wang CJ: Antitumor effects and preliminary systemic
toxicity of ANISpm in vivo and in vitro. Anticancer Drugs.
24:32–42. 2013. View Article : Google Scholar
|
|
100
|
Xie SQ, Zhang YH, Li Q, Xu FH, Miao JW,
Zhao J and Wang CJ: 3-Nitro-naphthalimide and nitrogen mustard
conjugate NNM-25 induces hepatocellular carcinoma apoptosis via
PARP-1/p53 pathway. Apoptosis. 17:725–734. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Tanaka T and Rabbitts TH: Interfering with
protein-protein interactions: Potential for cancer therapy. Cell
Cycle. 7:1569–1574. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Artavanis-Tsakonas S, Rand MD and Lake RJ:
Notch signaling: Cell fate control and signal integration in
development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Brou C, Logeat F, Gupta N, Bessia C,
LeBail O, Doedens JR, Cumano A, Roux P, Black RA and Israël A: A
novel proteolytic cleavage involved in Notch signaling: The role of
the disintegrin-metalloprotease TACE. Mol Cell. 5:207–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Ayaz F and Osborne BA: Non-canonical notch
signaling in cancer and immunity. Front Oncol. 4(345)2014.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wu L, Aster JC, Blacklow SC, Lake R,
Artavanis-Tsakonas S and Griffin JD: MAML1, a human homologue of
Drosophila mastermind, is a transcriptional co-activator for NOTCH
receptors. Nat Genet. 26:484–489. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Villanueva A, Alsinet C, Yanger K, Hoshida
Y, Zong Y, Toffanin S, Rodriguez-Carunchio L, Solé M, Thung S,
Stanger BZ, et al: Notch signaling is activated in human
hepatocellular carcinoma and induces tumor formation in mice.
Gastroenterology. 143:1660–1669.e7. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Liu M, Lee DF, Chen CT, Yen CJ, Li LY, Lee
HJ, Chang CJ, Chang WC, Hsu JM, Kuo HP, et al: IKKα activation of
NOTCH links tumorigenesis via FOXA2 suppression. Mol Cell.
45:171–184. 2012. View Article : Google Scholar :
|
|
108
|
Nüsslein-Volhard C and Wieschaus E:
Mutations affecting segment number and polarity in Drosophila.
Nature. 287:795–801. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Pepinsky RB, Zeng C, Wen D, Rayhorn P,
Baker DP, Williams KP, Bixler SA, Ambrose CM, Garber EA, Miatkowski
K, et al: Identification of a palmitic acid-modified form of human
Sonic hedgehog. J Biol Chem. 273:14037–14045. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Porter JA, Young KE and Beachy PA:
Cholesterol modification of hedgehog signaling proteins in animal
development. Science. 274:255–259. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Marigo V, Davey RA, Zuo Y, Cunningham JM
and Tabin CJ: Biochemical evidence that patched is the Hedgehog
receptor. Nature. 384:176–179. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Stone DM, Hynes M, Armanini M, Swanson TA,
Gu Q, Johnson RL, Scott MP, Pennica D, Goddard A, Phillips H, et
al: The tumour-suppressor gene patched encodes a candidate receptor
for Sonic hedgehog. Nature. 384:129–134. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Taipale J, Cooper MK, Maiti T and Beachy
PA: Patched acts catalytically to suppress the activity of
Smoothened. Nature. 418:892–897. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Sicklick JK, Li YX, Jayaraman A, Kannangai
R, Qi Y, Vivekanandan P, Ludlow JW, Owzar K, Chen W, Torbenson MS,
et al: Dysregulation of the Hedgehog pathway in human
hepato-carcinogenesis. Carcinogenesis. 27:748–757. 2006. View Article : Google Scholar
|
|
115
|
Patil MA, Zhang J, Ho C, Cheung ST, Fan ST
and Chen X: Hedgehog signaling in human hepatocellular carcinoma.
Cancer Biol Ther. 5:111–117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Zheng X, Zeng W, Gai X, Xu Q, Li C, Liang
Z, Tuo H and Liu Q: Role of the Hedgehog pathway in hepatocellular
carcinoma (Review). Oncol Rep. 30:2020–2026. 2013.PubMed/NCBI
|
|
117
|
Koyabu Y, Nakata K, Mizugishi K, Aruga J
and Mikoshiba K: Physical and functional interactions between Zic
and Gli proteins. J Biol Chem. 276:6889–6892. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Wang YY, Jiang JX, Ma H, Han J, Sun ZY,
Liu ZM and Xu ZG: Role of ZIC1 methylation in hepatocellular
carcinoma and its clinical significance. Tumour Biol. 35:7429–7433.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Badouel C, Garg A and McNeill H: Herding
Hippos: Regulating growth in flies and man. Curr Opin Cell Biol.
21:837–843. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Dong J, Feldmann G, Huang J, Wu S, Zhang
N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D:
Elucidation of a universal size-control mechanism in Drosophila and
mammals. Cell. 130:1120–1133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zhou D, Conrad C, Xia F, Park JS, Payer B,
Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, et al: Mst1 and
Mst2 maintain hepatocyte quiescence and suppress hepatocellular
carcinoma development through inactivation of the Yap1 oncogene.
Cancer Cell. 16:425–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Aragón E, Goerner N, Xi Q, Gomes T, Gao S,
Massagué J and Macias MJ: Structural basis for the versatile
interactions of Smad7 with regulator WW domains in TGF-β pathways.
Structure. 20:1726–1736. 2012. View Article : Google Scholar
|
|
123
|
Strano S, Munarriz E, Rossi M, Castagnoli
L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G and Blandino G:
Physical interaction with Yes-associated protein enhances p73
transcriptional activity. J Biol Chem. 276:15164–15173. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Komuro A, Nagai M, Navin NE and Sudol M:
WW domain-containing protein YAP associates with ErbB-4 and acts as
a co-transcriptional activator for the carboxyl-terminal fragment
of ErbB-4 that translocates to the nucleus. J Biol Chem.
278:33334–33341. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Yagi R, Chen LF, Shigesada K, Murakami Y
and Ito Y: A WW domain-containing yes-associated protein (YAP) is a
novel transcriptional co-activator. EMBO J. 18:2551–2562. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Wang W, Huang J and Chen J:
Angiomotin-like proteins associate with and negatively regulate
YAP1. J Biol Chem. 286:4364–4370. 2011. View Article : Google Scholar :
|
|
127
|
Chan SW, Lim CJ, Chong YF, Pobbati AV,
Huang C and Hong W: Hippo pathway-independent restriction of TAZ
and YAP by angiomotin. J Biol Chem. 286:7018–7026. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q
and Guan KL: Angiomotin is a novel Hippo pathway component that
inhibits YAP oncoprotein. Genes Dev. 25:51–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Oka T, Remue E, Meerschaert K, Vanloo B,
Boucherie C, Gfeller D, Bader GD, Sidhu SS, Vandekerckhove J,
Gettemans J, et al: Functional complexes between YAP2 and ZO-2 are
PDZ domain-dependent, and regulate YAP2 nuclear localization and
signalling. Biochem J. 432:461–472. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Oka T, Mazack V and Sudol M: Mst2 and Lats
kinases regulate apoptotic function of Yes kinase-associated
protein (YAP). J Biol Chem. 283:27534–27546. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Li H, Wolfe A, Septer S, Edwards G, Zhong
X, Abdulkarim AB, Ranganathan S and Apte U: Deregulation of Hippo
kinase signalling in human hepatic malignancies. Liver Int.
32:38–47. 2012. View Article : Google Scholar
|
|
133
|
Vassilev A, Kaneko KJ, Shu H, Zhao Y and
DePamphilis ML: TEAD/TEF transcription factors utilize the
activation domain of YAP65, a Src/Yes-associated protein localized
in the cytoplasm. Genes Dev. 15:1229–1241. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Zhao B, Kim J, Ye X, Lai ZC and Guan KL:
Both TEAD-binding and WW domains are required for the growth
stimulation and oncogenic transformation activity of yes-associated
protein. Cancer Res. 69:1089–1098. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Pobbati AV and Hong W: Emerging roles of
TEAD transcription factors and its coactivators in cancers. Cancer
Biol Ther. 14:390–398. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Rao VS, Srinivas K, Sujini GN and Kumar
GN: Protein-protein interaction detection: Methods and analysis.
Int J Proteomics. 2014(147648)2014. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
London AS, Patel K, Quinn L and Lemmerer
M: Application of coupled affinity-sizing chromatography for the
detection of proteolyzed HSA-tagged proteins. Protein Expr Purif.
180:80–84. 2014.
|
|
138
|
Tong AH, Evangelista M, Parsons AB, Xu H,
Bader GD, Pagé N, Robinson M, Raghibizadeh S, Hogue CW, Bussey H,
et al: Systematic genetic analysis with ordered arrays of yeast
deletion mutants. Science. 294:2364–2368. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Song Z, Dong C, Wang L, Chen DE, Bi G, Dai
M and Liu J: A novel method for purifying bluetongue virus with
high purity by co-immunoprecipitation with agarose protein A. Virol
J. 7(126)2010.
|
|
140
|
Rigaut G, Shevchenko A, Rutz B, Wilm M,
Mann M and Séraphin B: A generic protein purification method for
protein complex characterization and proteome exploration. Nat
Biotechnol. 17:1030–1032. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
141
|
MacBeath G and Schreiber SL: Printing
proteins as microarrays for high-throughput function determination.
Science. 289:1760–1763. 2000.PubMed/NCBI
|
|
142
|
Westwick JK and Michnick SW:
Protein-fragment complementation assays (PCA) in small GTPase
research and drug discovery. Methods Enzymol. 407:388–401. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Palmer AG III: Enzyme dynamics from NMR
spectroscopy. Acc Chem Res. 48:457–465. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Vidal M and Fields S: The yeast two-hybrid
assay: Still finding connections after 25 years. Nat Methods.
11:1203–1206. 2014. View Article : Google Scholar
|
|
145
|
Güell O, Sagués F and Serrano MA:
Essential plasticity and redundancy of metabolism unveiled by
synthetic lethality analysis. PLOS Comput Biol. 10:e10036372014.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Zhang Y, Jin Q, Wang S and Ren R: Modeling
and prediction of peptide drift times in ion mobility spectrometry
using sequence-based and structure-based approaches. Comput Biol
Med. 41:272–277. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Vyas VK, Goel A, Ghate M and Patel P:
Ligand and structure-based approaches for the identification of
SIRT1 activators. Chem Biol Interact. 228:9–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Enright AJ, Iliopoulos I, Kyrpides NC and
Ouzounis CA: Protein interaction maps for complete genomes based on
gene fusion events. Nature. 402:86–90. 1999.PubMed/NCBI
|
|
149
|
Foster HA, Estrada-Girona G, Themis M,
Garimberti E, Hill MA, Bridger JM and Anderson RM: Relative
proximity of chromosome territories influences chromosome exchange
partners in radiation-induced chromosome rearrangements in primary
human bronchial epithelial cells. Mutat Res. 756:66–77. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Pazos F and Valencia A: In silico
two-hybrid system for the selection of physically interacting
protein pairs. Proteins. 47:219–227. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Whidden C and Matsen FA IV: Quantifying
MCMC exploration of phylogenetic tree space. Syst Biol. 64:472–491.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Altman J, Hédl R, Szabó P, Mazůrek P,
Riedl V, Müllerová J, Kopecký M and Doležal J: Tree-rings mirror
management legacy: Dramatic response of standard oaks to past
coppicing in Central Europe. PLoS One. 8:e557702013. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Gene Ontology, C; Gene and Ontology
Consortium: Gene Ontology Consortium: Going forward. Nucleic Acids
Res. 43(D1): D1049–D1056. 2015. View Article : Google Scholar
|
|
154
|
Xenarios I, Salwínski L, Duan XJ, Higney
P, Kim SM and Eisenberg D: DIP, the Database of Interacting
Proteins: A research tool for studying cellular networks of protein
interactions. Nucleic Acids Res. 30:303–305. 2002. View Article : Google Scholar :
|
|
155
|
Chatr-Aryamontri A, Breitkreutz BJ,
Oughtred R, Boucher L, Heinicke S, Chen D, Stark C, Breitkreutz A,
Kolas N, O'Donnell L, et al: The BioGRID interaction database: 2015
update. Nucleic Acids Res. 43(D1): D470–D478. 2015. View Article : Google Scholar
|
|
156
|
Cowley MJ, Pinese M, Kassahn KS, Waddell
N, Pearson JV, Grimmond SM, Biankin AV, Hautaniemi S and Wu J: PINA
v2.0: Mining interactome modules. Nucleic Acids Res. 40(D1):
D862–D865. 2012. View Article : Google Scholar :
|
|
157
|
Patil A, Nakai K and Nakamura H:
HitPredict: A database of quality assessed protein-protein
interactions in nine species. Nucleic Acids Res. 39(Database):
D744–D749. 2011. View Article : Google Scholar
|
|
158
|
Hermjakob H, Montecchi-Palazzi L,
Lewington C, Mudali S, Kerrien S, Orchard S, Vingron M, Roechert B,
Roepstorff P, Valencia A, et al: IntAct: An open source molecular
interaction database. Nucleic Acids Res. 32:D452–D455. 2004.
View Article : Google Scholar :
|
|
159
|
Prieto C and De Las Rivas J: APID: Agile
Protein Interaction DataAnalyzer. Nucleic Acids Res. 34(Web
Server): W298–W302. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Licata L, Briganti L, Peluso D, Perfetto
L, Iannuccelli M, Galeota E, Sacco F, Palma A, Nardozza AP,
Santonico E, et al: MINT, the molecular interaction database: 2012
update. Nucleic Acids Res. 40(D1): D857–D861. 2012. View Article : Google Scholar :
|
|
161
|
Song JJ and Lee YJ: Dissociation of Akt1
from its negative regulator JIP1 is mediated through the
ASK1-MEK-JNK signal transduction pathway during metabolic oxidative
stress: A negative feedback loop. J Cell Biol. 170:61–72. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Kim J, Kang D, Sun BK, Kim JH and Song JJ:
TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically
modulated by the Src/CIN85/c-Cbl complex. Cell Signal. 25:372–379.
2013. View Article : Google Scholar
|
|
163
|
Deregibus MC, Cantaluppi V, Doublier S,
Brizzi MF, Deambrosis I, Albini A and Camussi G: HIV-1-Tat protein
activates phosphatidylinositol 3-kinase/AKT-dependent survival
pathways in Kaposi's sarcoma cells. J Biol Chem. 277:25195–25202.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Polzien L, Baljuls A, Rennefahrt UE,
Fischer A, Schmitz W, Zahedi RP, Sickmann A, Metz R, Albert S, Benz
R, et al: Identification of novel in vivo phosphorylation sites of
the human proapoptotic protein BAD: Pore-forming activity of BAD is
regulated by phosphorylation. J Biol Chem. 284:28004–28020. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Xiang T, Ohashi A, Huang Y, Pandita TK,
Ludwig T, Powell SN and Yang Q: Negative regulation of AKT
activation by BRCA1. Cancer Res. 68:10040–10044. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Xiang T, Jia Y, Sherris D, Li S, Wang H,
Lu D and Yang Q: Targeting the Akt/mTOR pathway in Brca1-deficient
cancers. Oncogene. 30:2443–2450. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Du K and Montminy M: CREB is a regulatory
target for the protein kinase Akt/PKB. J Biol Chem.
273:32377–32379. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Matsuzaki H, Daitoku H, Hatta M, Aoyama H,
Yoshimochi K and Fukamizu A: Acetylation of Foxo1 alters its
DNA-binding ability and sensitivity to phosphorylation. Proc Natl
Acad Sci USA. 102:11278–11283. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Brent MM, Anand R and Marmorstein R:
Structural basis for DNA recognition by FoxO1 and its regulation by
posttranslational modification. Structure. 16:1407–1416. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Biggs WH III, Meisenhelder J, Hunter T,
Cavenee WK and Arden KC: Protein kinase B/Akt-mediated
phosphorylation promotes nuclear exclusion of the winged helix
transcription factor FKHR1. Proc Natl Acad Sci USA. 96:7421–7426.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Yang H, Zhao R, Yang HY and Lee MH:
Constitutively active FOXO4 inhibits Akt activity, regulates p27
Kip1 stability, and suppresses HER2-mediated tumorigenicity.
Oncogene. 24:1924–1935. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Matsuzaki H, Ichino A, Hayashi T, Yamamoto
T and Kikkawa U: Regulation of intracellular localization and
transcriptional activity of FOXO4 by protein kinase B through
phosphorylation at the motif sites conserved among the FOXO family.
J Biochem. 138:485–491. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Zhu QS, Rosenblatt K, Huang KL, Lahat G,
Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, et al:
Vimentin is a novel AKT1 target mediating motility and invasion.
Oncogene. 30:457–470. 2011. View Article : Google Scholar
|
|
174
|
Drendall CI, Pham QH and Dietze EC:
Purification and characterization of recombinant CH3 domain
fragment of the CREB-binding protein. Protein Expr Purif.
70:196–205. 2010. View Article : Google Scholar :
|
|
175
|
Connor MK, Azmi PB, Subramaniam V, Li H
and Seth A: Molecular characterization of ring finger protein 11.
Mol Cancer Res. 3:453–461. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Yang WL, Wang J, Chan CH, Lee SW, Campos
AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, et al: The E3
ligase TRAF6 regulates Akt ubiquitination and activation. Science.
325:1134–1138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Hartman AD, Wilson-Weekes A, Suvannasankha
A, Burgess GS, Phillips CA, Hincher KJ, Cripe LD and Boswell HS:
Constitutive c-jun N-terminal kinase activity in acute myeloid
leukemia derives from Flt3 and affects survival and proliferation.
Exp Hematol. 34:1360–1376. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Kim CK, Lee SB, Nguyen TL, Lee KH, Um SH,
Kim J and Ahn JY: Long isoform of ErbB3 binding protein, p48,
mediates protein kinase B/Akt-dependent HDM2 stabilization and
nuclear localization. Exp Cell Res. 318:136–143. 2012. View Article : Google Scholar
|
|
179
|
Deep G, Oberlies NH, Kroll DJ and Agarwal
R: Isosilybin B causes androgen receptor degradation in human
prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.
Oncogene. 27:3986–3998. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Milne D, Kampanis P, Nicol S, Dias S,
Campbell DG, Fuller-Pace F and Meek D: A novel site of AKT-mediated
phosphorylation in the human MDM2 oncoprotein. FEBS Lett.
577:270–276. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Facchinetti V, Ouyang W, Wei H, Soto N,
Lazorchak A, Gould C, Lowry C, Newton AC, Mao Y, Miao RQ, et al:
The mammalian target of rapamycin complex 2 controls folding and
stability of Akt and protein kinase C. EMBO J. 27:1932–1943. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Oh WJ, Wu CC, Kim SJ, Facchinetti V,
Julien LA, Finlan M, Roux PP, Su B and Jacinto E: mTORC2 can
associate with ribosomes to promote cotranslational phosphorylation
and stability of nascent Akt polypeptide. EMBO J. 29:3939–3951.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Glidden EJ, Gray LG, Vemuru S, Li D,
Harris TE and Mayo MW: Multiple site acetylation of Rictor
stimulates mammalian target of rapamycin complex 2
(mTORC2)-dependent phosphorylation of Akt protein. J Biol Chem.
287:581–588. 2012. View Article : Google Scholar :
|
|
184
|
Fan CD, Lum MA, Xu C, Black JD and Wang X:
Ubiquitin-dependent regulation of phospho-AKT dynamics by the
ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1
response. J Biol Chem. 288:1674–1684. 2013. View Article : Google Scholar :
|
|
185
|
Persaud A, Alberts P, Amsen EM, Xiong X,
Wasmuth J, Saadon Z, Fladd C, Parkinson J and Rotin D: Comparison
of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2
using proteome arrays. Mol Syst Biol. 5(333)2009. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Mistafa O, Ghalali A, Kadekar S, Högberg J
and Stenius U: Purinergic receptor-mediated rapid depletion of
nuclear phosphorylated Akt depends on pleckstrin homology domain
leucine-rich repeat phosphatase, calcineurin, protein phosphatase
2A, and PTEN phosphatases. J Biol Chem. 285:27900–27910. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Woods NT, Mesquita RD, Sweet M, Carvalho
MA, Li X, Liu Y, Nguyen H, Thomas CE, Iversen ES Jr, Marsillac S,
et al: Charting the landscape of tandem BRCT domain-mediated
protein interactions. Sci Signal. 5:rs62012. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Sarbassov DD, Ali SM, Sengupta S, Sheen
JH, Hsu PP, Bagley AF, Markhard AL and Sabatini DM: Prolonged
rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell.
22:159–168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Ikenoue T, Inoki K, Yang Q, Zhou X and
Guan KL: Essential function of TORC2 in PKC and Akt turn motif
phosphorylation, maturation and signalling. EMBO J. 27:1919–1931.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Chen CH, Shaikenov T, Peterson TR,
Aimbetov R, Bissenbaev AK, Lee SW, Wu J, Lin HK and Sarbassov D: ER
stress inhibits mTORC2 and Akt signaling through GSK-3β-mediated
phosphorylation of rictor. Sci Signal. 4:ra102011. View Article : Google Scholar
|
|
191
|
Sundaresan NR, Pillai VB, Wolfgeher D,
Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta
M and Gupta MP: The deacetylase SIRT1 promotes membrane
localization and activation of Akt and PDK1 during tumorigenesis
and cardiac hypertrophy. Sci Signal. 4:ra462011. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Gao D, Inuzuka H, Tseng A, Chin RY, Toker
A and Wei W: Phosphorylation by Akt1 promotes cytoplasmic
localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction.
Nat Cell Biol. 11:397–408. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Romano D, Matallanas D, Weitsman G,
Preisinger C, Ng T and Kolch W: Proapoptotic kinase MST2
coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt.
Cancer Res. 70:1195–1203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Kim D, Shu S, Coppola MD, Kaneko S, Yuan
ZQ and Cheng JQ: Regulation of proapoptotic mammalian ste20-like
kinase MST2 by the IGF1-Akt pathway. PLoS One. 5:e96162010.
View Article : Google Scholar : PubMed/NCBI
|
